FASN and obesity disorder: EGCG produced a decrease in EGFR protein levels in T790M+ GR models, which is in agreement with Ali et al., who observed an EGFR decrease in sensitive and resistant PC9 cells treated with Orlistat, a FDA-approved FASN inhibitor for obesity management [41].